CoChat

Chemotherapeutic drugs and human tumor cells cytokine network

Open access
Levina, Vera, Su, Yunyun, Nolen, Brian, Liu, Xiaoning, Gordin, Yuri, Lee, Melissa, Lokshin, Anna, Gorelik, Elieser · 2008 · International Journal of Cancer
Cited by 90

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The ability of human tumor cell lines to produce various cytokines, chemokines, angiogenic and growth factors was investigated using Luminex multiplex technology. Media conditioned by tumor cells protected tumor cells from drug‐induced apoptosis and stimulated tumor cell proliferation. Antibodies neutralizing IL‐6, CXCL8, CCL2 and CCL5 blocked this stimulation. Treatment of tumor cells with doxorubicin and cisplatin resulted in a substantial increase in the production of IL‐6, CXCL8, CCL2, CCL5, BFGF, G‐CSF and VEGF. This stimulation was associated with drug‐induced activation of NF‐κB, AP‐1, AP‐2, CREB, HIF‐1, STAT‐1, STAT‐3, STAT‐5 and ATF‐2 transcription factors and upregulation of IL‐6, CXCL8, FGF‐2, CSF‐3 and CCL5 gene expression. Treatment of tumor cells with doxorubicin and antibodies neutralizing G‐CSF, CCL2 or CCL5 had higher inhibitory effects than each modality used alone. These results indicate that chemokines and growth factors produced by tumor by binding to the cognate receptors on tumor and stroma cells could provide proliferative and antiapoptotic signals helping tumor to escape drug‐mediated destruction. Clinical studies showed that antibodies neutralizing VEGF (Avastin/Bevacizumab) or blocking HER2/neu signaling (Herceptin/Trastuzumab) could increase the efficacy of chemotherapy, although these beneficial effects have been limited. It is possible that drug‐stimulated production of growth and proangiogenic factors could counterbalance the effects of antibody therapy. In addition, numerous growth factors and chemokines share angiogenic and growth‐stimulating properties, and thus reduction of a single factor is insufficient to completely block tumor growth. Thus, a broad disruption of tumor cytokine network is needed to further increase the efficacy of cancer therapy. © 2008 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.23732

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 49

  1. 10.1016/S0065-230X(05)93005-4 · DOI
  2. 10.1038/nrc905 · DOI · Paper page
  3. 10.1016/S0065-230X(08)60305-X · DOI · Paper page
  4. 10.1078/0171-9335-00349 · DOI
  5. 10.1083/jcb.141.7.1659 · DOI · Paper page
  6. 10.1016/S0002-9440(10)64058-8 · DOI · Paper page
  7. 10.1083/jcb.129.5.1177 · DOI · Paper page
  8. 10.1158/0008-5472.CAN-05-0623 · DOI · Paper page
  9. 10.1016/S0140-6736(94)90387-5 · doi:10.1016/s0140-6736(94)90387-5
  10. 10.1182/blood.V95.8.2630 · DOI · Paper page
  11. 10.1002/ijc.10833 · DOI · Paper page
  12. 10.1159/000028045 · DOI · Paper page
  13. 10.1080/13684730050515868 · DOI
  14. Xu L, 2000, Interleukin 8: an autocrine growth factor for human ovarian cancer, Oncol Res, 12, 97, 10.3727/096504001108747567 · DOI
  15. 10.1016/j.ejca.2006.01.006 · DOI · Paper page
  16. Azenshtein E, 2002, The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity, Cancer Res, 62, 1093
  17. 10.1007/s10555-006-9003-5 · DOI · Paper page
  18. 10.1182/blood.V96.1.34 · DOI · Paper page
  19. 10.1016/j.semcancer.2003.10.006 · DOI · Paper page
  20. 10.1158/1078-0432.CCR-06-0074 · DOI · Paper page
  21. 10.1007/BF02785841 · DOI
  22. 10.1158/1078-0432.CCR-04-0812 · DOI · Paper page
  23. 10.1016/0002-9378(91)90582-C · DOI · Paper page
  24. Schneider GP, 2001, The diverse role of chemokines in tumor progression: prospects for intervention (Review), Int J Mol Med, 8, 235
  25. 10.1016/j.bbrc.2005.05.132 · DOI · Paper page
  26. 10.1056/NEJMoa052122 · DOI · Paper page
  27. 10.1200/JCO.2004.11.070 · DOI
  28. Lev DC, 2003, Dacarbazine causes transcriptional up‐regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy, Mol Cancer Ther, 2, 753
  29. 10.4049/jimmunol.172.10.6330 · doi:10.4049/jimmunol.172.10.6330
  30. 10.1002/ijc.10842 · DOI
  31. 10.1089/154065803322302826 · DOI · Paper page
  32. 10.1158/1055-9965.EPI-04-0404 · DOI · Paper page
  33. 10.1158/1078-0432.CCR-06-1805 · DOI · Paper page
  34. 10.1089/adt.2006.4.293 · DOI
  35. 10.1002/mc.20217 · DOI · Paper page
  36. 10.1038/nri887 · DOI · Paper page
  37. 10.1016/S1054-3589(08)60111-8 · DOI · Paper page
  38. 10.1038/sj.onc.1204383 · DOI · Paper page
  39. 10.1172/JCI25740 · DOI · Paper page
  40. 10.1002/pros.20306 · DOI · Paper page
  41. 10.1038/sj.bjc.6690164 · DOI · Paper page
  42. Choi C, 2001, Fas‐induced expression of chemokines in human glioma cells: involvement of extracellular signal‐regulated kinase 1/2 and p38 mitogen‐activated protein kinase, Cancer Res, 61, 3084
  43. 10.1016/j.yexcr.2007.12.027 · DOI
  44. 10.1073/pnas.0402048101 · DOI
  45. 10.4049/jimmunol.172.9.5467 · DOI · Paper page
  46. 10.1002/ijc.23324 · DOI
  47. Talapatra S, 2001, Growth factor signaling in cell survival: implications for cancer treatment, J Pharmacol Exp Ther, 298, 873, 10.1016/S0022-3565(24)29451-9 · DOI
  48. 10.1038/nrc1650 · DOI · Paper page
  49. 10.1158/0008-5472.CAN-07-0905 · DOI · Paper page

Cited by

See all 90

Metadata

Authors
Levina, V., Su, Y., Nolen, B., Liu, X., Gordin, Y., Lee, M., Lokshin, A., & Gorelik, E.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2008-08-25
Volume
123
Issue
9
Pages
2031-2040
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2051043829
Cited by
90
References
3
FWCI
4.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.